Orasi service aims to cuts costs in Alzheimer’s trials

By Nick Taylor

- Last updated on GMT

Related tags: Nervous system, Central nervous system

Orasi Medical claims CROs and pharmas can cut the cost and length of Alzheimer’s trials, and improve accuracy, by using its brain function measuring service, which is now being promoted in Japan.

Clinical trials of Alzheimer’s drugs, and other central nervous system (CNS) therapeutics, can be long and expensive, with no guarantee they will be successful, but Orasi believes it can improve this situation.

Speaking to Outsourcing-Pharma Joseph Baxter, Orasi’s representative director, Asia-Pacific and Europe, explained that its Synchronous Neural Interaction Test (SNI Test) is more reliable and robust than the alternatives.

These include MRI, PET and biomarkers but Baxter believes they all have weaknesses, such as unreliability, invasiveness, not giving a complete picture or taking a long time to convey information.

In contrast Orasi’s service uses technology, mainly manufactured by Elekta, which can give a full brain scan in 10 minutes. Currently pharma companies are using this in conjunction with the other tests and Orasi is expanding the service to improve management of these multiple data sets.

By adding a neuro analytics database to the offering Orasi’s clients will be able to combine, organise and analyse data from multiple sources, including MRI, PET and biomarkers.

Targeting CROs & international expansion

Orasi is beginning to target its services at CROs, which Baxter believes currently provide imaging with inferior accuracy than his company can provide. Consequently the company is hoping CROs will use the service as part of their offering to pharma clients.

Currently no CROs are using Orasi’s service, as the initial focus was on pharma companies, but Baxter is aiming to work with them and clients in Japan to expand its user base.

An office has been established in Tokyo, Japan and this is the initial focus of Orasi’s international expansion, because of its aging population and the time it takes to enter the market, but Baxter is pursuing further opportunities.

He explained that Europe, in particular the UK, Germany and France, are the company’s next geographic targets because of the large numbers of pharmas in the region.

Baxter added that Orasi’s business model allows it to use any site where the scanning equipment is located. However, this also highlights a shortcoming of the service, with the cost of the equipment meaning there are a limited number of the scanners.

Related news

Show more

Related products

show more

What’s Next for mRNA?

What’s Next for mRNA?

Catalent Pharma Solutions | 27-Jan-2022 | Insight Guide

Now that the pharma industry and regulators have significant data on safety and efficacy of mRNA vaccines, many companies are looking beyond infectious...

SmartSignals Study Oversight

SmartSignals Study Oversight

Signant Health | 24-Jan-2022 | Product Brochure

Today, sponsors and study teams often struggle to support the growing variety and volume of clinical data. The right technology thought will help your...

The APAC Advantages

The APAC Advantages

Catalent Pharma Solutions | 18-Jan-2022 | Insight Guide

Over recent years, the Asia-Pacific (APAC) region has become an emerging market for pharmaceutical and biotech innovation, including clinical studies.

CellCarta - Mapping Precision Medicine

CellCarta - Mapping Precision Medicine

CellCarta | 17-Jan-2022 | Product Presentation

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers

Follow us

Products

View more

Webinars